AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12464983
Drug: Quinapril (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (titrated up to 40 mg daily)
Trial: 2475322
Drug: Ethanol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.75 mg/kg)
Trial: 319408
Drug: Beclamid (3-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclamid (3-6 tablets a day according to weight)
Trial: 23939537
Drug: Zolpidem sublingual
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem sublingual tablet (ZST) 3.5 mg in fed state
Trial: 23939537
Drug: Zolpidem sublingual
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem sublingual tablet (ZST) 3.5 mg in fasting state
Trial: 23939537
Drug: Zolpidem sublingual
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem sublingual tablet (ZST) in fed state
Trial: 23939537
Drug: Zolpidem sublingual
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem sublingual tablet (ZST) in fasting state
Trial: 21878080
Drug: Fenofibrate (Tricor)
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate (Tricor) administered early (first 7 days) after myocardial revascularization
Trial: 2371597
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil (5-FU) continuous regimen (5% cream applied nightly for 6 weeks)
Trial: 2371597
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil (5-FU) periodic regimen (5% cream applied 2 consecutive nights per week for 10 weeks)
Trial: 345887
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release ephedrine-theophylline-phenobarbital (ETP) tablet
Trial: 345887
Drug: Terbutaline tablets
RxNorm normalized name: terbutaline Oral Tablet
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline tablets
Trial: 28841649
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose prednisolone (FIN-RACo DMARD combination)
Trial: 28841649
Drug: Infliximab added
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab added on to the FIN-RACo DMARD combination
Trial: 28841649
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added on to the FIN-RACo DMARD combination
Trial: 12515749
Drug: Control (dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (dietary therapy alone)
Trial: 9890856
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy for 2 months
Trial: 2296877
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of oral anticoagulants (Group A)
Trial: 2296877
Drug: Aspirin, 650
RxNorm normalized name: Aspirin, 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 650 mg/day (Group B)
Trial: 2296877
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic therapy (Group C)
Trial: 6971092
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg intravenous every 4 hours for 48 hours, followed by 1 g oral daily for 10 days)
Trial: 30847561
Drug: Inositol 2
RxNorm normalized name: inositol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol 2 g plus 200 µg of folic acid (twice daily for 3 months)
Trial: 30847561
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg daily plus 200 µg of folic acid
Trial: 30847561
Drug: Letrozole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 7.5 mg per day for 5 days (with folic acid)
Trial: 30847561
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (200 µg of folic acid as placebo)
Trial: 23338657
Drug: Propiverine extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine extended-release (ER) 45 mg s.i.d.
Trial: 23338657
Drug: Propiverine immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine immediate-release (IR) 15 mg t.i.d.
Trial: 19728607
Drug: Standard AO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AO plate via L-shaped incision
Trial: 17503974
Drug: Aripiprazole 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10, 15, 20, or 30 mg/day
Trial: 7524460
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2 x 10(6) KIU in the pump prime solution)
Trial: 3066983
Drug: Bemithyl (actoprotective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemithyl (actoprotective agent)
Trial: 24094768
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg intravenously once every 2 weeks
Trial: 22937831
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 250 mg once a day
Trial: 17409822
Drug: Gemcitabine (1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1100 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 8) every 28 days
Trial: 17409822
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 1) every 21 days
Trial: 8736419
Drug: Orofacial physiotherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orofacial physiotherapeutic treatment (OPT)
Trial: 26066525
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (70 mg for 16 weeks)
Trial: 25274892
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 synthetic disease-modifying antirheumatic drugs (sDMARD) and prednisolone (PRD), with infliximab or placebo infusions during the first 6 months
Trial: 23239968
Drug: Inactivated subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated subunit influenza A (H7N7) vaccine 7.5 µg
Trial: 23239968
Drug: Inactivated subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated subunit influenza A (H7N7) vaccine 15 µg
Trial: 23239968
Drug: Inactivated subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated subunit influenza A (H7N7) vaccine 45 µg
Trial: 23239968
Drug: Inactivated subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated subunit influenza A (H7N7) vaccine 90 µg
Trial: 19882529
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium therapy (300 mg magnesium citrate for 1 month)
Trial: 14705233
Drug: N of
RxNorm normalized name: Antigen of mold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N of 1 trials with diclofenac 50 mg and misoprostol 200 microg twice a day for 2 weeks
Trial: 14705233
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (stopping NSAID and waiting)
Trial: 12085291
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) for plantar fasciitis
Trial: 12085291
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) for lateral elbow epicondylitis (tennis elbow)
Trial: 12085291
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) for calcifying tendinitis of the rotator cuff
Trial: 23997361
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance therapy (Thornton Adjustable Positioner type‐1, Airway Management, Inc., Dallas, TX, USA)
Trial: 12935441
Drug: Intravenous liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous liposomal all-trans-retinoic acid (L-ATRA) 90 mg/m² every other day for 15 days
Trial: 12935441
Drug: Oral ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ATRA (Vesanoid) 45 mg/m² daily for 15 days
Trial: 12935441
Drug: Intravenous liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous liposomal all-trans-retinoic acid (L-ATRA)
Trial: 12935441
Drug: Intravenous liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous liposomal all-trans-retinoic acid (L-ATRA) and Oral ATRA
Trial: 10827385
Drug: Conventional pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pretreatment (heparin and aspirin)
Trial: 31958293
Drug: Amoxicillin-metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-metronidazole
Trial: 12781596
Drug: tolcapone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (two doses)
Trial: 11187914
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment without asparaginase (ASP)
Trial: 11187914
Drug: 24-hour daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-hour daunorubicin (DNR) infusion
Trial: 11187914
Drug: 6-thioguanine (6-TG)
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-thioguanine (6-TG) in maintenance treatment
Trial: 11187914
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of systemic treatment
Trial: 1283570
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 480 mg/day
Trial: 1283570
Drug: Verapamil IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil IR (80 or 160 mg 3 times daily)
Trial: 31004517
Drug: Standard tablet
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tablet (ST‐OS)
Trial: 31004517
Drug: Suspension in
RxNorm normalized name: SUSPENSION IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension in solid lipid nanoparticles (SLN-OS)
Trial: 31004517
Drug: Transdermal jellified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal jellified melatonin microemulsion (μE-TD)
Trial: 25112783
Drug: Fiber treatment
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber treatment (Plantago ovata husk)
Trial: 22575433
Drug: Pictorial images
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pictorial images and electronic drug monitoring (EDM) review used in counseling
Trial: 19602273
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (24 weeks)
Trial: 24620666
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise therapy
Trial: 8849215
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (50,000 U/kg/day in two divided doses for 10 days)
Trial: 1627425
Drug: Neural-network-based artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural-network-based artificial intelligence for treatment decision-making
Trial: 27748575
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral care with tongue cleaning (intervention group; n = 58)
Trial: 27748575
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral care alone (control group; n = 56)
Trial: 22048283
Drug: Oral Passiflora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Passiflora incarnata Linneaus extract
Trial: 16003527
Drug: Ropinirole alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole alone or in combination with L-dopa
Trial: 11826422
Drug: Amantadine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Trial: 11826422
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly)
Trial: 11826422
Drug: Amantadine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (2 x 100 mg p.o. QD) with interferon alfa-2a
Trial: 10397536
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (20 mg pentavalent antimony per kg per day for 28 days)
Trial: 10397536
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.7 mg/kg per day for 28 days)
Trial: 6993035
Drug: Chemo-immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy with levamisole (2.5 mg/kg orally for 2 consecutive days each week while off chemotherapy)
Trial: 6993035
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (standard regimen of cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 6993035
Drug: Chemo-immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-immunotherapy with levamisole
Trial: 31430414
Drug: LINK (buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LINK (buprenorphine induction, in-patient dose stabilization and post-discharge transition to maintenance buprenorphine)
Trial: 29458934
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy with lavender oil for 5 sessions over 3 cycles
Trial: 16646673
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) plus G-CSF
Trial: 16646673
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) plus GM-CSF followed by G-CSF
Trial: 10962675
Drug: Full strength
RxNorm normalized name: Dakins Full Strength Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full strength Burow's solution (13% aluminium acetate)
Trial: 10962675
Drug: 3.25% aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.25% aluminium acetate solution (a quarter strength Burow's solution)
Trial: 10962675
Drug: 1.3% aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3% aluminium acetate solution (1/10 strength Burow's solution)
Trial: 27298569
Drug: Mirtazapine (MG)
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine (MG)
Trial: 27298569
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CG)
Trial: 25330631
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 2 years followed by 1 year follow-up and combined with 3-year drug therapy
Trial: 25330631
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only drug therapy
Trial: 18775608
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐estradiol
Trial: 10771880
Drug: IPV (Inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV (Inactivated Polio Vaccine)
Trial: 10771880
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of IPV starting from birth
Trial: 10771880
Drug: IPV/OPV at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV/OPV at birth followed by 3 doses of OPV
Trial: 10771880
Drug: Some vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Some vaccine at birth (IPV or OPV)
Trial: 10771880
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of IPV
Trial: 8183102
Drug: Sodium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium concentration of 0 mmol.l‐1
Trial: 8183102
Drug: Sodium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium concentration of 25 mmol.l‐1
Trial: 8183102
Drug: Sodium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium concentration of 50 mmol.l‐1
Trial: 3351300
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg (acute study)
Trial: 3351300
Drug: Nisoldipine 25
RxNorm normalized name: nisoldipine 25.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 25 mg (chronic study)
Trial: 25823403
Drug: NaOCl +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOCl + triple antibiotic paste (TAP) for 4 weeks followed by EDTA
Trial: 25823403
Drug: NaOCl +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaOCl + diluted triple antibiotic paste (DTAP) for 4 weeks followed by EDTA
Trial: 23307511
Drug: Tα1 administration
RxNorm normalized name: 1-T
DrugBank: 1-Testosterone (DB01481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tα1 administration for 2 weeks
Trial: 23307511
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Tα1 administration)
Trial: 23307511
Drug: Tα1 administration
RxNorm normalized name: 1-T
DrugBank: 1-Testosterone (DB01481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tα1 administration
Trial: 11406837
Drug: Education package
RxNorm normalized name: zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Education package for the treatment of menorrhagia given to doctors at a primary care level
Trial: 30470924
Drug: Immediate postpartum
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate postpartum availability of the contraceptive implant
Trial: 24057996
Drug: Topiramate/Nicotine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate/Nicotine patch (TOP/NIC)
Trial: 2372267
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily + Aspirin 600 mg three times a day
Trial: 20620742
Drug: High-flavanol intervention
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flavanol intervention (HiFI) [375 mg]
Trial: 20620742
Drug: Low-flavanol intervention
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flavanol intervention (LoFI) [9 mg]
Trial: 9797692
Drug: Pamidronate 300
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 300 mg daily
Trial: 2202024
Drug: Sprotte cannula
RxNorm normalized name: CANNULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprotte cannula (24 G)
Trial: 2202024
Drug: Quincke cannula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quincke cannula (25 G)
Trial: 64803
Drug: Bendrofluazide 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 5 mg and 10 mg
Trial: 64803
Drug: Prazosin 2
RxNorm normalized name: prazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 2 mg three times daily (rising to 5 mg if required)
Trial: 64803
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs (beta blockade, bendrofluazide, and prazosin)
Trial: 24462960
Drug: 1.7% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7% hypertonic saline solution supplemented with 40 mg furosemide (salt infusion group)
Trial: 24462960
Drug: Glucose supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose supplemented with 40 mg furosemide (glucose infusion group)